B. Riley Has Pessimistic View of Harrow FY2027 Earnings

Harrow, Inc. (NASDAQ:HROW - Free Report) - Stock analysts at B. Riley reduced their FY2027 earnings estimates for shares of Harrow in a research note issued on Wednesday, May 28th. B. Riley analyst M. Mamtani now expects that the company will earn $4.46 per share for the year, down from their prior estimate of $4.79. B. Riley has a "Buy" rating and a $65.00 price objective on the stock. The consensus estimate for Harrow's current full-year earnings is ($0.53) per share.

Harrow (NASDAQ:HROW - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, missing analysts' consensus estimates of $0.02 by ($0.40). Harrow had a negative net margin of 19.75% and a negative return on equity of 45.57%. The company had revenue of $47.83 million for the quarter, compared to analyst estimates of $57.00 million.

Separately, HC Wainwright upped their price objective on shares of Harrow from $57.00 to $60.00 and gave the company a "buy" rating in a research note on Monday, May 12th.

Harrow Trading Up 3.8%

Shares of NASDAQ HROW traded up $1.04 on Thursday, reaching $28.24. 642,462 shares of the company traded hands, compared to its average volume of 497,600. Harrow has a fifty-two week low of $16.71 and a fifty-two week high of $59.23. The company has a 50 day moving average of $25.18 and a 200 day moving average of $30.54. The company has a current ratio of 1.55, a quick ratio of 1.44 and a debt-to-equity ratio of 3.23. The stock has a market capitalization of $1.04 billion, a PE ratio of -30.04 and a beta of 0.41.

Institutional Trading of Harrow

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. increased its position in Harrow by 0.3% during the 4th quarter. Vanguard Group Inc. now owns 1,872,100 shares of the company's stock worth $62,809,000 after purchasing an additional 5,225 shares in the last quarter. Braidwell LP increased its position in Harrow by 5.5% during the 1st quarter. Braidwell LP now owns 956,839 shares of the company's stock worth $25,452,000 after purchasing an additional 49,800 shares in the last quarter. D. E. Shaw & Co. Inc. increased its position in Harrow by 6.7% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 664,714 shares of the company's stock worth $22,301,000 after purchasing an additional 41,896 shares in the last quarter. Royce & Associates LP increased its position in Harrow by 12.0% during the 1st quarter. Royce & Associates LP now owns 327,096 shares of the company's stock worth $8,701,000 after purchasing an additional 35,006 shares in the last quarter. Finally, Northern Trust Corp increased its position in Harrow by 7.5% during the 4th quarter. Northern Trust Corp now owns 319,084 shares of the company's stock worth $10,705,000 after purchasing an additional 22,266 shares in the last quarter. Institutional investors and hedge funds own 72.76% of the company's stock.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.